Venous thromboembolism in patients with glioblastoma multiforme.

被引：0
|
作者：
Edwin, Natasha
Khorana, Alok A.
Khoury, Michael
Barnett, Gene H.
Ahluwalla, Manmeet Singh
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Univ Rochester, Rochester, NY USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2068
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Determining viability of using APNG status as a prognostic marker in patients with glioblastoma multiforme.
    Dahlrot, Rikke Hedegaard
    Hellwege, Sofie
    Fosmark, Sigurd
    Jensen, Kristian Lindstroem
    Lohse, Jesper
    Derand, Helene
    Hjelmborg, Jacob
    Hansen, Steinbjorn
    Kristensen, Bjarne Winther
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] An oxygenation agent and radiation sensitizer, dodecafluoropentane, for the treatment of glioblastoma multiforme.
    Lickliter, Jason D.
    Wilson, David Brown
    Hendrickson, Howard
    Raghunand, Natarajan
    Khor, Soo-Peang
    Longacre, Olivia
    Unger, Evan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Blood group B is a potent risk factor for venous thromboembolism in glioblastoma multiforme
    Heenkenda, K. M.
    Malmstrom, A.
    Lysiak, M.
    Mudaisi, M.
    Bratthall, C.
    Milos, P.
    Strandeus, M.
    Akesson, L.
    Soderkvist, P.
    Uppugunduri, S.
    Osman, A. M.
    THROMBOSIS RESEARCH, 2021, 200 : S80 - S80
  • [24] Using a prospective comprehensive database to define features that impact the outcome of patients with glioblastoma multiforme.
    Field, K. M.
    Rosenthal, M.
    Kosmider, S.
    Gibbs, P.
    Drummond, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Distance to the Neurooncological Center: A Negative Prognostic Factor in Patients with Glioblastoma Multiforme. An Epidemiological Study
    Kerschbaumer, Johannes
    Freyschlag, Christian Franz
    Bauer, Richard
    Obwegeser, Alois Albert
    Schubert, Gerrit Alexander
    Thome, Claudius
    Seiz, Marcel
    ANTICANCER RESEARCH, 2012, 32 (12) : 5515 - 5519
  • [26] ACCURATE PREDICTION OF SURVIVAL IN GLIOBLASTOMA MULTIFORME. A MACHINE LEARNING TOOL
    Ruiz-Patino, A.
    NEURO-ONCOLOGY, 2017, 19 : 80 - 80
  • [27] Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki, T.
    Mizutani, T.
    Nojima, K.
    Takagi, T.
    Okumura, R.
    Yuba, Y.
    Ueba, T.
    Takahashi, J. A.
    Miyatake, S.
    Nozaki, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Synthetic LDL as targeted drug delivery vehicle for glioblastoma multiforme.
    Nikanjam, M
    Blakely, EA
    Bjornstad, KA
    Forte, TM
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9003S - 9004S
  • [29] Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study
    Fountzilas, G
    Karavelis, A
    Capizzello, A
    Kalogera-Fountzila, A
    Karkavelas, G
    Zamboglou, N
    Selviaridis, P
    Foroglou, G
    Tourkantonis, A
    JOURNAL OF NEURO-ONCOLOGY, 1999, 45 (02) : 159 - 165
  • [30] Radiation and Concomitant Weekly Administration of Paclitaxel in Patients with Glioblastoma Multiforme. A Phase II Study
    George Fountzilas
    Antonios Karavelis
    Antonio Capizzello
    Anna Kalogera-Fountzila
    George Karkavelas
    Nikolaos Zamboglou
    Panayiotis Selviaridis
    George Foroglou
    Achilles Tourkantonis
    Journal of Neuro-Oncology, 1999, 45 : 159 - 165
12345